A patient with Guillain-Barre syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barre syndrome such as interleukin-2, interferon-γ, and tumor necrosis factor-α. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.
|Number of pages||3|
|Journal||Journal of Neurology, Neurosurgery and Psychiatry|
|Publication status||Published - 1998|
- Guillian-Barre syndrome
ASJC Scopus subject areas
- Neuropsychology and Physiological Psychology
- Psychiatry and Mental health